Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with Aojing Medical (688613.SH) leading the "degradable semi-hydrated calcium sulfate" project [1][2]. Industry Overview - Biomedical materials are referred to as the "chip of medical devices" and are crucial for the localization of high-end medical equipment. However, China faces significant challenges in the fields of degradable bone repair materials and magnesium alloys, with over 60% of the high-end bone repair materials market being occupied by imported products [1][2]. - The current market for bone repair materials is dominated by foreign companies that monopolize core technologies, leading to high prices and clinical standard dominance, which exacerbates accessibility issues for domestic patients [1]. Company Positioning - Aojing Medical is recognized as a leading enterprise in the field of mineralized collagen bone repair materials, with a strong commitment to long-term R&D investment and a multidisciplinary research team [2][3]. - The company has accumulated substantial technical reserves in key areas such as high-end regenerative medical materials and advanced manufacturing processes, and has undertaken numerous national and provincial major R&D projects [2]. Strategic Importance - The successful selection in the "revealing the list" initiative signifies national endorsement of Aojing Medical's technological route and R&D capabilities, positioning the company as a leader in the domestic high-end bone repair materials sector [3][4]. - Aojing Medical aims to collaborate with universities and hospitals to tackle key technical challenges, conduct multi-center clinical trials, and establish clinical standards, thereby shortening product launch cycles and enhancing the overall value of China's biomedical materials industry [3]. Market Potential - The market for bone repair materials in China is projected to exceed 35 billion yuan by 2030, with a domestic production rate expected to surpass 70%. The share of degradable materials is anticipated to increase from 15% to 40% [3].

Core Viewpoint - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of selected units for the innovative task of biomedical materials, with Aojing Medical (688613.SH) leading the "degradable semi-hydrated calcium sulfate" project team, highlighting the company's role in addressing the domestic challenges in high-end bone repair materials [1][2]. Industry Overview - Biomedical materials are referred to as the "chips of medical devices" and are crucial for the localization of high-end medical equipment. Currently, over 60% of the high-end bone repair materials market in China is dominated by imported products, leading to high costs and clinical standard monopolization by foreign companies [1][2]. - The degradable semi-hydrated calcium sulfate is a revolutionary material in bone defect repair, offering advantages such as good biocompatibility, self-curing properties, and adaptability to complex bone defects. However, the core technical challenge lies in maintaining a dynamic balance between degradation and bone regeneration [1][3]. Company Insights - Aojing Medical is recognized as a leading enterprise in the field of mineralized collagen bone repair materials, with a strong commitment to long-term R&D investment and a multidisciplinary research team. The company has accumulated significant technical reserves in key areas such as high-end regenerative medical materials and advanced manufacturing processes [2][3]. - The successful selection in the "revealing the list" initiative signifies Aojing Medical's leadership in the domestic high-end bone repair materials sector. The company aims to collaborate with universities and hospitals to tackle key technical challenges and streamline clinical standard development, thereby enhancing its integrated industry chain from material research to clinical application [3][4]. Market Potential - Under the guidance of the "Healthy China 2030" strategy, the biomedical materials industry is entering a golden development period. According to Frost & Sullivan, the market size for bone repair materials in China is expected to exceed 35 billion yuan by 2030, with the localization rate likely surpassing 70%. The proportion of degradable materials is projected to increase from the current 15% to 40% [3].

Core Viewpoint - The company is holding a temporary shareholders' meeting on July 11, 2025, to discuss adjustments to fundraising projects and their implementation details [1][2][10]. Group 1: Meeting Procedures - The meeting will start at 14:30 and will require attendees to sign in 30 minutes prior [2][5]. - Only shareholders, directors, supervisors, senior management, and authorized personnel are allowed to attend [1]. - Voting will be conducted both on-site and online, with specific time slots for each method [3][6]. Group 2: Fundraising and Investment Projects - The company raised approximately RMB 547.67 million through an initial public offering, with a net amount of RMB 500.82 million after expenses [10]. - The company plans to adjust the implementation subject and location of certain fundraising projects, specifically canceling the involvement of its subsidiary in Jiaxing [12][14]. - New projects will include "Mineralized Collagen/Sulfate/Phosphate Calcium Self-setting Bone Cement," which aims to address the increasing incidence of bone defects [15][16]. Group 3: Project Adjustments - The "Aojing Health Technology Industrial Park Construction Project" will now be managed by Beijing Aojing Medical Device Co., Ltd. instead of Jiaxing Aojing [12][14]. - The project will cease funding for the "Artificial Skin" sub-project due to unsatisfactory progress and will focus on the new sub-project [14][16]. - The adjustments are intended to enhance project management and ensure effective use of raised funds [12][16].

Core Viewpoint - Aojing Medical (688613) is undergoing adjustments to its fundraising projects, including changes in implementation subjects and locations, which are deemed necessary for the company's development and efficiency in using raised funds [1][2][3]. Company Announcements - Aojing Medical's second supervisory board meeting approved two resolutions: one regarding the postponement of certain fundraising projects, and the other concerning adjustments to the implementation subjects and locations of these projects [1][4]. - The company will hold its first extraordinary shareholders' meeting on July 11, 2025, to review the adjustments to the fundraising projects [1][4]. Fundraising Project Adjustments - As of December 31, 2024, Aojing Medical's fundraising projects include the Aojing Health Technology Industrial Park construction and other projects, with a total planned investment of 500.82 million yuan [2][3]. - The Aojing Health Technology Industrial Park construction project has been postponed from June 30, 2025, to June 30, 2027, due to strategic adjustments and the impact of national procurement policies [3]. - The company has canceled the implementation of the project by its subsidiary in Jiaxing and will return the remaining raised funds to its dedicated account [2].